An experimental once-daily tablet that works in a similar way to Viagra has shown potential in slowing the progression of early Alzheimer's disease, according to findings from a global clinical trial.
The drug, known as AR1001, belongs to a class of medications called PDE5 inhibitors, which relax blood vessels and increase blood flow. In a late-stage study involving 604 people with early-stage Alzheimer's who were not taking other treatments, AR1001 reduced cognitive decline and memory loss by 31% compared with a placebo.
The results, presented at the Clinical Trials on Alzheimer's Disease conference in the United States, were not statistically significant in a broader group of patients who were also taking other Alzheimer's medications, the South Korean manufacturer AriBio acknowledged.
A new approach to treatment
Experts have welcomed the findings as a potential step forward in the search for therapies that address the underlying causes of Alzheimer's rather than just managing symptoms. Richard Oakley, associate director for research and innovation at the Alzheimer's Society, said: "These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms."
AR1001 is being developed specifically for Alzheimer's, unlike Viagra, which is used for erectile dysfunction. Oakley cautioned against using Viagra off-label for dementia, noting that AR1001 has been designed with the disease in mind.
The trial, conducted across 13 countries, reported mostly mild to moderate side effects, including diarrhoea, falls, and dizziness. AriBio said it plans to discuss the findings with the U.S. Food and Drug Administration (FDA) to determine next steps.
Alzheimer's is the most common form of dementia, affecting an estimated 57 million people worldwide. There is currently no cure, and existing treatments only slow symptom progression in some patients. The search for disease-modifying therapies remains a priority for researchers and health systems across Europe, where ageing populations are driving rising dementia rates.
Oakley added: "We look forward to seeing the full results from this trial and how this drug progresses."
The announcement comes as European healthcare systems grapple with the growing burden of neurodegenerative diseases. While the results are promising, experts stress that larger, longer-term studies are needed to confirm AR1001's efficacy and safety before it could be considered for regulatory approval in the EU or elsewhere.
For now, the drug remains experimental, and patients are advised to consult their doctors about established treatments and clinical trial opportunities.


